OBJECTIVES: HIV-1-infected persons spontaneously controlling viremia without treatment (SCV) are rare. Sex and race effects on prevalence and outcome are poorly defined, and it is unclear whether SCV qualitatively or quantitatively differs from typical infection. These issues are examined in this article. DESIGN: Medical records of 46 524 persons receiving outpatient care for HIV-1 infection were reviewed. Of these, 29 811 had adequate viremia testing for SCV screening. METHODS: SCV was defined as at least three consecutive plasma viremia measurements <50 RNA copies/ml spanning at least 1 year without treatment. SCV loss was defined as at least three consecutive viremia measurements ≥50 RNA copies/ml or one ≥1000 RNA copies/ml. Demographics of persons with SCV were compared with the total population. Viremia and blood CD4 T-cell levels during SCV were compared between demographic subgroups and persons who maintained or lost SCV during observation. RESULTS: In total, 53 persons (0.18%) met SCV criteria. Prevalence was higher for women versus men and blacks versus whites; these appeared independent. Loss of SCV was observed at 1.22% per year, and significantly associated with viremia 'blips'. Blip magnitudes fit log-normal distributions with means below 50 RNA copies/ml. CONCLUSION: Our novel observation of higher SCV prevalence in women and blacks is consistent with prior studies of typical chronic infection. Viremia blips correspond to greater risk of loss of SCV, likely reflecting higher set-point viremia under the limit of detection. Our findings suggest that SCV represents an extreme along a continuum of HIV-1 infection, and not qualitative difference.
OBJECTIVES:HIV-1-infectedpersons spontaneously controlling viremia without treatment (SCV) are rare. Sex and race effects on prevalence and outcome are poorly defined, and it is unclear whether SCV qualitatively or quantitatively differs from typical infection. These issues are examined in this article. DESIGN: Medical records of 46 524 persons receiving outpatient care for HIV-1 infection were reviewed. Of these, 29 811 had adequate viremia testing for SCV screening. METHODS:SCV was defined as at least three consecutive plasma viremia measurements <50 RNA copies/ml spanning at least 1 year without treatment. SCV loss was defined as at least three consecutive viremia measurements ≥50 RNA copies/ml or one ≥1000 RNA copies/ml. Demographics of persons with SCV were compared with the total population. Viremia and blood CD4 T-cell levels during SCV were compared between demographic subgroups and persons who maintained or lost SCV during observation. RESULTS: In total, 53 persons (0.18%) met SCV criteria. Prevalence was higher for women versus men and blacks versus whites; these appeared independent. Loss of SCV was observed at 1.22% per year, and significantly associated with viremia 'blips'. Blip magnitudes fit log-normal distributions with means below 50 RNA copies/ml. CONCLUSION: Our novel observation of higher SCV prevalence in women and blacks is consistent with prior studies of typical chronic infection. Viremia blips correspond to greater risk of loss of SCV, likely reflecting higher set-point viremia under the limit of detection. Our findings suggest that SCV represents an extreme along a continuum of HIV-1 infection, and not qualitative difference.
Authors: Florencia Pereyra; Sarah Palmer; Toshiyuki Miura; Brian L Block; Ann Wiegand; Alissa C Rothchild; Brett Baker; Rachel Rosenberg; Emily Cutrell; Michael S Seaman; John M Coffin; Bruce D Walker Journal: J Infect Dis Date: 2009-09-15 Impact factor: 5.226
Authors: Sophie Grabar; Hana Selinger-Leneman; Sophie Abgrall; Gilles Pialoux; Laurence Weiss; Dominique Costagliola Journal: AIDS Date: 2009-06-01 Impact factor: 4.177
Authors: Jason F Okulicz; Vincent C Marconi; Michael L Landrum; Scott Wegner; Amy Weintrob; Anuradha Ganesan; Braden Hale; Nancy Crum-Cianflone; Judith Delmar; Vincent Barthel; Gerald Quinnan; Brian K Agan; Matthew J Dolan Journal: J Infect Dis Date: 2009-12-01 Impact factor: 5.226
Authors: Mariya V Sivay; Jessica M Fogel; Jing Wang; Yinfeng Zhang; Estelle Piwowar-Manning; William Clarke; Autumn Breaud; Joel Blankson; Erica L Hamilton; Kathleen Kahn; Amanda Selin; F Xavier Gomez-Olive; Catherine MacPhail; James P Hughes; Audrey Pettifor; Susan H Eshleman Journal: HIV Clin Trials Date: 2018-12-06
Authors: David R Collins; Jonathan M Urbach; Zachary J Racenet; Umar Arshad; Karen A Power; Ruchi M Newman; Geetha H Mylvaganam; Ngoc L Ly; Xiaodong Lian; Anna Rull; Yelizaveta Rassadkina; Adrienne G Yanez; Michael J Peluso; Steven G Deeks; Francesc Vidal; Mathias Lichterfeld; Xu G Yu; Gaurav D Gaiha; Todd M Allen; Bruce D Walker Journal: Immunity Date: 2021-09-07 Impact factor: 43.474
Authors: Peter Zuidewind; Mark Cotton; Shaun Barnabas; Anita Janse Van Rensburg; Gert van Zyl; Carli Gordijn Journal: S Afr J Infect Dis Date: 2022-06-30
Authors: Samara Tatielle M Gomes; Érica R Gomes; Mike B Dos Santos; Sandra S Lima; Maria Alice F Queiroz; Luiz Fernando A Machado; Izaura M V Cayres-Vallinoto; Antonio Carlos R Vallinoto; Marluísa de O Guimarães Ishak; Ricardo Ishak Journal: BMC Infect Dis Date: 2017-06-01 Impact factor: 3.090
Authors: Vinicius A Vieira; Peter Zuidewind; Maximilian Muenchhoff; Julia Roider; Jane Millar; Margaret Clapson; Anriette Van Zyl; Delane Shingadia; Emily Adland; Rohin Athavale; Nicholas Grayson; M Azim Ansari; Christian Brander; Claudia Fortuny Guash; Lars Naver; Thanyawee Puthanakit; Wipaporn Natalie Songtaweesin; Jintanat Ananworanich; Denise Peluso; Beatriz Thomé; Jorge Pinto; Pieter Jooste; Gareth Tudor-Williams; Mark F Cotton; Philip Goulder Journal: AIDS Date: 2019-01-27 Impact factor: 4.177